Income Taxes (Narrative) (Detail) (USD $)	12 Months Ended					12 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012 Utah Research And Development Tax Credits [Member]	Jun. 30, 2012 Utah [Member]	May 31, 2011 Rules-Based Medicine, Inc [Member]	Jun. 30, 2011 Prior [Member]	Jun. 30, 2011 Subsequent [Member]	Dec. 31, 2011 Foreign And State Net Operating Losses [Member]
Income Tax Disclosure [Line Items]
Reversal of additional valuation allowance		$ 35,024,000
Amount of valuation allowance increased								1,851,000
Excess tax benefits incurred	(34,193,000)	(58,831,000)				(31,653,000)	(27,178,000)
Deferred tax asset	36,220,000	35,653,000			2,104,000
Total federal and alternative minimum tax net operating loss carry-forwards	7,252,000
Research and development tax credits	401,000		7,637,000
Federal and alternative minimum tax net operating loss carry-forwards, expiration dates	2030 through 2031
Foreign net operating losses	7,006,000
Utah net operating loss carry-forwards	229,900,000
Utah net operating loss carry-forwards, expiration dates	2015 through 2028
Federal tax due resulting in net of tax credits			4,964,000
Utah research and development tax credit carry-forwards expire			2025 through 2030
Excess tax benefits attributable to deferred tax asset	7,781,000	6,530,000		92,557,000
Remaining excess tax benefits not included in deferred tax assets				137,343,000
Valuation allowance prior to adoption of guidance note which offset deferred tax asset	3,008,000
Valuation allowance to offset valuation allowance	1,553,000
Valuation allowance to offset foreign and miscellaneous state net operating loss carry-forwards	2,052,000
Cumulative effect	$ 0